Parkinson's Disease Drug Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028

The Global Parkinson's disease market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD). Recently, there have been some major product launches in Parkinson's disease. For instance, in February 2022, Avion Pharmaceuticals LLC announced the commercial launch of DHIVY, the first and only carbidopa/ levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in Nov 2021. This unique design enables more precise medication for those with Parkinson's disease (PD). Also, government funding for research and massive utilization of L-Dopa, asymptomatic dopamine replacement treatment, and the nigrostriatal system expects a boost to the market in the coming years.

A full report of Parkinson's Disease Drug Market is available at: https://www.omrglobal.com/industry-reports/parkinsons-disease-drug

The shifting of research activities from symptomatic treatment to Parkinson's disorder modifying treatment will create growth for Parkinson's disease treatment industry over the forthcoming years. For instance, Kyowa Kirin Co Ltd a Japanese Pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). For instance, in Feb 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age or older. It can be taken with or without food.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/parkinsons-disease-drug

Market Coverage

• The market number available for - 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered- By Mechanism of Action
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Land- AbbVie Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Bausch Health Companies Inc., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Parkison's Disease Drug Market Report Segment

By Mechanism of Action

• Dopamine Agonists
• Anticholinergic
• MAO-B Inhibitors
• Amantadine
• Carbidopa-levodopa
• COMT Inhibitors
• Others

Global Parkinson's Disease Drug Market-Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AbbVie Inc
• Apotex Inc
• Axovant Gene Therapies Ltd
• Boston Scientific Corp
• Cipla Inc
• Eisai Co Ltd
• Eli Lily & Co
• Impax Laboratories Inc
• Mylan NV
• Novartis International AG
• Pfizer Inc
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd
• Wockhardt Ltd
• Orion Corp

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.